6. Waterhouse D, Lam J, Betts KA, et al. Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset. Data Brief. 2021;37:107195. doi:10.1016/...
6. Waterhouse D, Lam J, Betts KA, et al. Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset. Data Brief. 2021;37:107195. doi:10.1016/j.dib.2021.107195. 7.https://www.targetedonc.com/view/io...
6. Waterhouse D, Lam J, Betts KA, et al. Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset. Data Brief. 2021;37:107195. doi:10.1016/j.dib.2021.107195. 7.https://www.targetedonc.com/view/io...
NotreatmentImmunotherapy Immunodoublets TargetedTherapysequencing(chemoorRT) Nivolumab:SquamousCellCa Nivolumab:Non-squamous OverallSurvival 100 NivolumabDocetaxel 90(n292)(n290) 80 mOS,mo12.29.4 70 HR0.73(96%CI:0.59,0.89);P0.0015 60 ) 1-yrOSrate51% ...
We propose that PDL1 is upregulated within the tumor in response to immunotherapy, but can be blocked to restore effective anti-tumor immune responses.Joseph AntoniosHoracio SotoRobert HarrisDavid NathansonSam SadeghiBenjamin EllingsonLinda Liau
Understand the prognostic effect of PDL1 expression, infiltration by CD8+ and CD3+ T cells in gastric cancer (GC) might help the identification of candidate patient who might benefit from immunotherapy. Methods: Immunohistochemistry were performed on a tissue microarray including 1,014 GC specimens ...
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may ...
(P0.05).Conclusion:PD-L1isexpressedinthelivercancerandcanceradjacenttissues.PD-L1inlivertissueofpositiveexpressionratewashigherthantheorganizationandthenormaltissuecancer.PD-L1moleculeisanewpromisingbiomarkerforprevention,diagnosisandprognosisoflivercancer.ItsuggestedthatPD-L1isanewtargetforlivercancerimmunotherapysince...
Abstract: GS1-00 Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial (来源:《肿瘤瞭望》编辑部) 版权声明 凡署名原创的文章版权属《肿瘤瞭望》所有。欢迎个人转发分享。其他任何媒体、网站如需转载或引用本网版...
Simultaneously targeting PDL1 and LDHA, which would combine immunotherapy and metabolically targeted treatments, might shed some light on the treatment of breast cancer, especially TNBC.Background Programmed death ligand 1 (PDL1) is highly expressed on the surface of a variety of cancer cells. It ...